Want to see ATYR full AI Analyst Report?
ATYR Stock Chart & Stats
$0.57
-$0.02(-4.98%)
At close: 4:00 PM EDT
$0.57
-$0.02(-4.98%)
Day’s Range― - ―
52-Week Range$0.17 - $1.11
Previous CloseN/A
Volume825.96K
Average Volume (3M)6.16M
Market Cap
$16.84M
Enterprise Value$12.22M
Total Cash (Recent Filing)$57.42M
Total Debt (Recent Filing)$11.30M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 05, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding98,087,425
10 Day Avg. Volume1,897,121
30 Day Avg. Volume6,156,021
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.25
P/FCF Ratio-1.17
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue64.29
Enterprise Value/Gross Profit-0.54
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$1.00Price Target Upside75.44% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 Regulatory AlignmentFDA alignment on the Phase 3 design reduces regulatory uncertainty around efzofitimod’s next development stage. A defined randomized study, clinical endpoints, and planned initiation provide a clearer path toward testing efficacy in a population with significant unmet medical need.
Exclusive Global Efzofitimod RightsRegaining exclusive worldwide rights gives aTyr control over efzofitimod’s development, regulatory strategy, and potential commercialization across interstitial lung disease. This consolidates the asset under one owner and preserves future strategic options for partnerships or financing.
Modest LeverageRelatively modest leverage limits the direct burden of debt service compared with a highly indebted balance sheet. This provides some financial flexibility while the company advances its clinical program, although operating losses and cash usage still weaken overall funding resilience.
Bears Say
Persistent Cash BurnPersistent operating and free cash flow deficits indicate that the business does not currently fund its activities internally. Continued clinical development therefore depends on external financing, partnerships, or other capital sources, increasing funding risk over the next several quarters.
Minimal Revenue And Deep LossesMinimal and volatile revenue combined with recurring operating, EBITDA, and net losses shows that aTyr remains a pre-profit biotech without meaningful commercial traction. The limited revenue base provides little support for absorbing development costs or reducing dependence on capital markets.
Eroding Asset And Equity BaseDeclining assets and equity reflect the cumulative effect of losses and cash consumption on the company’s capital base. If operating results do not improve, further erosion could reduce financial flexibility and increase the amount of outside funding needed to sustain development.
aTyr Pharma News
ATYR FAQ
What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was $0.17 and its highest was $1.11 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is $16.84M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on Aug 07, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.121 by $0.011.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -0.1.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 98,087,425 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.121. Following the earnings report the stock price went up 3.327%.
Which hedge fund is a major shareholder of aTyr Pharma?
Currently, no hedge funds are holding shares in ATYR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
aTyr Pharma
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
ATYR Stock 12 Month Forecast
Average Price Target
$1.00
▲(75.44% Upside)
Technical Analysis
XBiotech
―
―
Prelude Therapeutics
―
Context Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
2.55% Insiders
26.37% Mutual Funds
<0.01% Other Institutional Investors
67.30% Public Companies and
Individual Investors